Sign In
Buy TLTFF
$0.166
+0.0001 (+0.0602%)
At Close: Jun 23, 2026
Theralase(R) Demonstrates Effective Treatment of Herpes
04:15pm, Wednesday, 12'th Feb 2025
Theralase® validates previous University of Manitoba research by demonstrating that RuvidarTM is safe and effective in the treatment of the Herpes Simplex Virus in an animal model. TORONTO, ON / ACCE
Theralase(R) Releases Latest Research on Inactivation of Herpes Simplex Viruses
07:00am, Monday, 10'th Feb 2025
University of Manitoba independent research verifies that RuvidarTM is more effective than acyclovir in the inactivation of Herpes Simplex Viruses post infection. TORONTO, ON / ACCESS Newswire / Febru
Theralase(R) Interim Clinical Data to be Presented at the 2025 AUA Annual Meeting
04:15pm, Monday, 27'th Jan 2025
TORONTO, ON / ACCESS Newswire / January 27, 2025 / Theralase® Technologies Inc. ("Theralase®" or the "Company") (TSXV:TLT)(OTCQB:TLTFF), a clinical stage pharmaceutical company dedicated to the rese
Theralase(R) Launches Three New Clinical Study Sites in USA
08:05am, Monday, 09'th Dec 2024
Associated Medical Professionals of NY, Urology of Indiana and Central Ohio Urology Group are the latest three US-based study sites for clinical research of Theralase®'s bladder cancer treatment TORO
Theralase(R) Launches New Clinical Study Site in Canada
07:00am, Thursday, 05'th Dec 2024
St. Joseph's Healthcare Hamilton is the latest Canadian clinical study site for clinical investigation of Theralase®'s Anti-Cancer Therapy for the treatment of bladder cancer TORONTO, ON / ACCESSWIRE
Theralase Technologies Inc. (TLTFF) Q3 2024 Earnings Call Transcript
12:55pm, Wednesday, 04'th Dec 2024
Theralase Technologies Inc. (OTCQX:TLTFF) Q3 2024 Earnings Conference Call December 4, 2024 11:00 AM ET Company Participants Matthew Perraton - Chairman of the Board Kristina Hachey - Chief Financial
Theralase continued to advance bladder cancer study during Q3
08:45am, Thursday, 28'th Nov 2024
Theralase Technologies Inc (TSX-V:TLT, OTCQB:TLTFF) during the third quarter continued to make significant progress in its Study II clinical trial, which focuses on the treatment of BCG-unresponsive n
Theralase(R) Release's 3Q2024 Financial Statements
05:05pm, Wednesday, 27'th Nov 2024
TORONTO, ON / ACCESSWIRE / November 27, 2024 / Theralase® Technologies Inc. (" Theralase® " or the " Company ") (TSXV:TLT)(OTCQB:TLTFF), a clinical stage pharmaceutical company dedicated to the rese
Theralase Technologies completes private placement to support Phase 2 bladder cancer study
09:31am, Friday, 15'th Nov 2024
Theralase Technologies Inc (TSX-V:TLT, OTCQB:TLTFF) announced that it has completed a non-brokered private placement, raising approximately $666,400 through the issuance of 2,221,334 units at $0.30 pe
Theralase(R) Closes Non-Brokered Private Placement
07:00am, Friday, 15'th Nov 2024
TORONTO, ON / ACCESSWIRE / November 15, 2024 / Theralase® Technologies Inc. ("Theralase®" or the "Company") (TSXV:TLT)(OTCQB:TLTFF), a clinical stage pharmaceutical company dedicated to the research
Theralase(R) Extends Warrants
06:30pm, Tuesday, 12'th Nov 2024
TORONTO, ON / ACCESSWIRE / November 12, 2024 / Theralase® Technologies Inc. ("Theralase ®" or the "Company") (TSXV:TLT)(OTCQB:TLTFF), a clinical stage pharmaceutical company dedicated to the researc
Theralase Technologies' bladder cancer treatment shows promising results in Phase 2 study - ICYMI
11:03am, Saturday, 12'th Oct 2024
Theralase Technologies Inc (TSX-V:TLT, OTCQB:TLTFF) CEO Roger Dumoulin-White joined Proactive to discuss the latest developments for the company's lead drug, Ruvidar, which is targeting non-muscle inv
Theralase Technologies reports positive interim results from bladder cancer study
09:39am, Monday, 07'th Oct 2024
Theralase Technologies Inc (TSX-V:TLT, OTCQB:TLTFF) has provided an update on its ongoing bladder cancer clinical study involving Ruvidar, its light-activated drug, which is being investigated for Bac
Theralase(R) Provides Update on Bladder Cancer Clinical Study
07:00am, Monday, 07'th Oct 2024
TORONTO, ON / ACCESSWIRE / October 7, 2024 / Theralase® Technologies Inc. ("Theralase®" or the "Company") (TSXV:TLT)(OTCQB:TLTFF), a clinical stage pharmaceutical company dedicated to the research a
Theralase Technologies announces closure of financing
09:25am, Wednesday, 25'th Sep 2024
Theralase Technologies Inc (TSX-V:TLT, OTCQB:TLTFF) has closed a non-brokered private placement, issuing 2.72 million units at $0.20 per unit, raising $544,000. Each unit includes one common share and
